Nimesulide has a known a pre-gastric absorption, so Zydis technology in which the drug can be formulated as an orally lyophilized tablet for intra-oral administration can be a successful idea for bypassing liver metabolism. AUC of nimesulide by Zydis technology is 62% higher when compared with conventional tablets. So, the dose of nimesulide can be reduced to obtain the same Cmax obtained with conventional tablets which consequently leads to side effect reduction.